← Leaderboards
Lili Wang
Dana-Farber Cancer Inst
$5,880,767
Attributed
$8,130,059
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,130,059 · 4
By mechanism
R01$8,130,059 · 4
Top collaborators
- Catherine Ju-Ying Wu5 shared
- Alexey V. Danilov1 shared
- Zheng Xia1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Lee Marshall Nadler$396,612,225
- Steven P. Balk$19,509,335
- Piotr Sicinski$42,703,610
- Peter M Howley$39,809,224
- Himisha Beltran$8,786,271
Others in their field
Other Emerging Leaders on “Mouse Model”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$13,186,126
- Nuno Macarico Da Costa · Allen Institute$11,726,937
- Forrest Christie Collman · Allen Institute$11,726,937
- Jacqueline K White · Jackson Laboratory$11,670,339
- Thomas Dick · Rbhs-New Jersey Medical School$11,611,284
Research focus
Mouse ModelGenesB-LymphocytesMolecularIn VivoMutationChronic Lymphocytic LeukemiaSamplingDisease ProgressionRna SplicingChronic Lymphocytic Leukemia CellGeneticCellsCancer CellResponseClinical TrialsAgedAtm Gene MutationLesionDna DamageFoundationsMarrowBloodBiology
Grant awards (14)
Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation$721,723
R01 · FY2025 · CA · contact PI
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia$648,241
R01 · FY2025 · CA · contact PI
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia$608,892
R01 · FY2024 · CA · contact PI
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia$402,484
R01 · FY2024 · CA · contact PI
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia$556,211
R01 · FY2023 · CA · contact PI
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia$415,196
R01 · FY2023 · CA · contact PI
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia$423,784
R01 · FY2022 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$538,977
R01 · FY2021 · CA
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia$428,050
R01 · FY2021 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$669,100
R01 · FY2020 · CA
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia$389,192
R01 · FY2020 · CA · contact PI
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$885,964
R01 · FY2019 · CA
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$740,321
R01 · FY2018 · CA
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia$701,924
R01 · FY2017 · CA